An International Research and Development Intellectual Rights Concept Clearing Warehouse
CapRegen is a newly incorporated public limited company that has been established in order to make investments in the global anti-ageing and regenerative medicine market place.
CapRegen PLC (’CapRegen’), the AIM listed anti-ageing and regenerative medicine investment company, this week publishes its Annual Report and Accounts for the year end 2007 (December 31, 2007)
Read More (3.2mb)
The Company will use the expertise of Dr Robert Goldman, PhD, DO, FAASP and Dr Ronald Klatz, DO, to invest in medical technologies that they and the other Directors believe have commercial viability. In order to commence this investment strategy, the Company is proposing to raise £3.2 million by way of the Placing and at the same time is applying for admission of its Ordinary Shares to trading on AIM.
Operating as a Research and Development intellectual rights concept clearing warehouse, CapRegen will capitalize on the network of 100,000 plus physicians, scientists, and health practitioners involved with, or affiliated with, the American Academy of Anti-Aging Medicine (A4M)
- Fund scientific researchers with early concept technologies with near term commercial viability
- Vend to technology customers interested in the commercially viable product
Site was last updated on: 04/02/2008